World-first gonorrhoea vaccine launched by NHS England as infections soar
It will not be available for everyone. The focus will mainly be on gay and bisexual men with a history of multiple sexual partners or an STI.
The vaccine is 30-40% effective, but NHS England hopes it will reverse soaring numbers of infections.
There were more than 85,000 cases in 2023 – the highest since records began in 1918.
Gonorrhoea does not always have symptoms, but they can include pain, unusual discharge, inflammation of the genitals and infertility.
How many people will chose to be immunised is uncertain.
But projections by Imperial College London show that if the jab proves popular then it could prevent 100,000 cases and save the NHS nearly £8m over the next decade.
Max, a sexual health campaigner, told BBC Newsbeat he would "100%" take the vaccine after being diagnosed with gonorrhoea twice within a year.
"I think this is great that it's been announced", he says, adding: "It's going to take the pressure off the clinics, it's just a big win all round."
Vaccination will start in August and will be offered through sexual health services.
Public Health Scotland said it was also working on plans to launch its own programme for high-risk individuals.
BBC Newsbeat has asked health bodies in Wales and Northern Ireland whether they intend to do the same.
This vaccine wasn't designed for gonorrhoea. It's the meningitis B vaccine currently given to babies.
But the bacteria that cause the two diseases are so closely related that the MenB jab appears to cut gonorrhoea cases by around a third.
That will require a delicate conversation in sexual health clinics as the vaccine will not eliminate the risk of catching gonorrhoea. It is normally caught while having sex without a condom.
But Prof Andrew Pollard, the chair of the Joint Committee on Vaccination and Immunisation (JCVI), which recommended the vaccine, said despite it only being 30% effective, it was "worth having" and could have "a huge impact" overall.
The decision is not just about the record numbers of cases. Gonorrhoea is becoming increasingly difficult to treat.
Most cases are treated with a single dose of antibiotics, but there is an 80-year history of the bacterium which causes gonorrhoea repeatedly evolving resistance to our antibiotics.
It's happening to the current treatments too and is why some doctors are concerned gonorrhoea could one-day become untreatable.
The best way to deal with a drug-resistant infection is to never catch it in the first place.
Dr Amanda Doyle, from NHS England, said: "The launch of a world-first routine vaccination for gonorrhoea is a huge step forward for sexual health and will be crucial in protecting individuals, helping to prevent the spread of infection and reduce the rising rates of antibiotic resistant strains of the bacteria."
The people most affected by gonorrhoea in the UK are those aged 16-to-25, gay and bisexual men, and those of black and Caribbean ancestry.
The vaccine – which costs around £8 per dose – is value for money when primarily offered to gay and bisexual men, rather than all teenagers.
However, clinicians do have the freedom to use their own judgement and offer the vaccine to people using sexual health services they think are of equally high risk.
People will be offered mpox (formerly known as monkeypox), HPV and hepatitis vaccines at the same time.
Potential new antibiotic for treating gonorrhoea
Don't ditch condoms, sexual health experts say
Prof Matt Phillips, president of the British Association for Sexual Health and HIV, said: "This is excellent news and a landmark moment for sexual health in England.
"Gonorrhoea diagnoses are at their highest since records began and this has the potential to help us to turn that around."
It is not known how long the protection provided by the vaccine will last or how often booster jabs might be required.
The decision comes almost a year and a half after a vaccination programme was recommended by the UK's JCVI.
Sexual health campaigners had criticised that long wait, but have welcomed this decision.
Katie Clark, head of policy and advocacy at the Terrance Higgins Trust, called it a "huge win".
Listen to Newsbeat live at 12:45 and 17:45 weekdays - or listen back here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
08-08-2025
- Yahoo
MAXONA Pharma seeks FDA approval for pain relief MAX-001
MAXONA Pharmaceuticals has submitted an investigational new drug (IND) application seeking approval from the US Food and Drug Administration (FDA) for its lead compound, MAX-001, to treat acute pain. The compound is being developed as a non-opioid, new molecular entity, non-steroidal anti-inflammatory drugs oral therapy for acute and chronic pain management. The company is developing MAX-001 as an optimised extended-release formulation of nefopam, which has been studied and prescribed outside the US as a non-scheduled moderate to severe acute and chronic pain treatment. MAXONA Pharmaceuticals president and CEO Shawn Fatholahi stated: "During the past six months, MAXONA has achieved a number of important MAX-001 development milestones. I am extremely proud of the remarkable commitment of the MAXONA team and look forward to initiating our Phase 2 study as soon as FDA clearance is received. 'With the submission of this IND, we are well-positioned to accelerate the development of MAX-001 and expand the options for safe and effective non-opioid analgesics available to healthcare practitioners to address the pain management needs of their patients." The therapy is specifically designed to provide rapid onset of pain relief as well as extended duration of analgesia. Its mechanism of action functions as a triple neurotransmitter reuptake inhibitor, exhibiting the highest potency for norepinephrine reuptake inhibition, followed by serotonin, and then dopamine. When approved for use in the US, MAX-001 will be the only triple monoamine reuptake inhibitor indicated for acute pain. In early 2025, Phase I clinical trial data of the therapy showed it to be well-tolerated among participants. There were no reported serious adverse events or early discontinuations due to related adverse events, and no concerning findings or abnormal trends were observed in ECGs, clinical labs and vital signs. "MAXONA Pharma seeks FDA approval for pain relief MAX-001" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-08-2025
- Yahoo
Thousands of patients miss out on weight loss jab due to NHS ‘postcode lottery'
Thousands of obese patients are missing out on a key weight loss jab due to a 'postcode lottery' of provision in the NHS, according to a report. Mounjaro, dubbed the 'King Kong' of weight loss medicine, was supposed to be available through GP surgeries from 23 June under an agreement between NHS England and NICE. But just eight out of 42 NHS Integrated Care Boards (ICBs) in England were able to provide treatment to patients, according to Sky News, who obtained the data using a Freedom of Information request. Many other ICBs were reportedly unable to confirm when treatment would be available. Dr Jonathan Hazlehurst, an endocrinologist and obesity physician at University Hospitals Birmingham, said patients were 'set up for failure' and have been treated unfairly. "Giving people open promises and setting them up for disappointment and failure is clearly grossly unfair. That's what the current system is doing,' he told the broadcaster. NICE said in December that the NHS should offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. It calculated from NHS England data that there were 97,500 patients who should be treated in the first year. But Dr Hazlehurst claims NHS England has only provided funding for just over 22,000 patients. The Independent has approached NHS England for comment. A spokesperson told Sky News that NHS England had "fully supported the rollout" of Mounjaro. "We issued guidance and provided funding in March to all Integrated Care Boards to support treatment costs, enable scaling of services and provide wrap-around care, including digital support services,' they said. It comes after NICE warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. The new 'quality standard' from NICE says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made.'
Medscape
01-08-2025
- Medscape
Chemotherapy Linked to Brain Atrophy in Breast
Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new findings from a pilot study suggested. Memory problems in patients with cancer may not stem solely from stress or anxiety related to their diagnosis but could reflect underlying changes in brain structure, study investigator Paul Edison, PhD, MPhil, professor of neuroscience and clinical professor of neurology at Imperial College London, London, England, told Medscape Medical News . While the findings suggest that chemotherapy may contribute to neuronal damage, the researchers noted that many aspects of the relationship between treatment and brain changes remain unclear. Edison highlighted three key areas that require further investigation — uncovering the mechanisms driving brain atrophy, determining the proportion of patients affected, and identifying effective prevention strategies. Another investigator on the study, Laura Kenny, MD, PhD, associate professor and consultant medical oncologist at Imperial College London, noted that the issue has received limited attention to date but expressed hope that the findings will raise awareness and encourage further research, given its clinical importance. The findings were presented on July 29 at the Alzheimer's Association International Conference (AAIC) 2025. Investigating Cognitive Impact Advances in chemotherapeutic agents have improved survival rates in patients with cancer. However, challenges persist regarding the long-term impact of these drugs. Chemotherapy-associated cognitive impairment, often referred to as 'brain fog' or 'chemobrain,' affects approximately one third of patients with breast cancer following treatment. While cognitive decline resolves within 12 months for some patients, others experience persistent effects that may elevate the risk for neurodegenerative conditions, Edison explained. To evaluate the impact of chemotherapy on the brain, investigators studied 328 women with nonmetastatic breast cancer who had undergone chemotherapy within the past 12 months. Patients received either anthracycline — a drug derived from the Streptomyces peucetius bacterium — or taxanes such as docetaxel and paclitaxel, both commonly used in breast cancer treatment, or a combination of these agents. In addition, some patients may also have had hormone therapy at some point during treatment, said Kenny. Participants completed neurocognitive prescreening tests every 3 months using a specialized artificial intelligence-driven platform, allowing them to take detailed memory assessments online from home. Among those prescreened, 18 individuals with lower neurocognitive scores (mean age, approximately 55 years) and 19 cognitively normal control individuals without breast cancer (mean age, approximately 67 years) underwent comprehensive, in-person, neurocognitive evaluations and MRI scans. Researchers analyzed the scans using region of interest (ROI) and voxel-based morphometry (VBM), which uses sophisticated computer software, to assess grey matter volumes and surface areas. The ROI analysis revealed significant reductions in gray matter volume (measured in mm3) and surface area (measured in mm2) among patients experiencing chemobrain, particularly affecting the isthmus cingulate and pars opercularis, with changes extending into the orbitofrontal and temporal regions. Significant Atrophy The VBM analysis confirmed significant atrophy in the frontal, parietal, and cingulate regions of patients with chemobrain compared with control individuals ( P < .05). Edison noted that this pattern overlaps with brain changes typically observed in Alzheimer's disease and vascular cognitive impairment. For both analyses, 'we demonstrated there is some amount of shrinkage in the brain among patients with chemobrain.' he said. 'The fact that controls are older means the results are even more significant as there's more brain atrophy as people age.' Some of the affected brain regions may be linked to impaired memory, a hallmark of Alzheimer's disease, but Edison cautioned that given the small sample size this finding should be interpreted with caution. While the analysis demonstrated overall lower brain volumes in patients with 'chemobrain' compared with controls, Edison emphasized that this finding reflects a single time point and does not indicate brain shrinkage over time. Other events, including stroke — can also cause brain changes. Edison highlighted the importance of determining the significance of these brain changes, how they affect patients and whether they can be prevented. In-person neurocognitive testing revealed significantly reduced semantic and verbal fluency, as well as lower Mini-Mental State Examination scores in patients with chemobrain. Edison noted that these results support the MRI findings. The team plans to follow patients to track brain changes and memory recovery, Kenny said. While patients with breast cancer are a common focus, the researchers intend to expand the study to other cancers in both men and women, said Kenny. Anecdotally, many patients report memory problems during chemotherapy, she added. Based on discussions with her oncology colleagues, Kenny noted that many patients anecdotally report experiencing memory problems during chemotherapy. More Research Needed Commenting for Medscape Medical News , Rebecca M. Edelmayer, PhD, vice president, Scientific Engagement, at the Alzheimer's Association, said the research may help shed light on why women are more likely to develop dementia than men. For years now, experts have been trying to figure out what puts women at higher risk for AD and other dementias, said Edelmayer. 'We still don't understand whether this involves biologically driven risk factors or socially driven risk factors.' Research linking treatments for other health conditions to increased memory problems may offer some clues, she noted, suggesting a potential avenue for further investigation into the intersection of chemotherapy and neurodegenerative diseases such as Alzheimer's. However, Edelmayer emphasized that this line of research is still in its infancy. Much more work is needed to determine whether there is a direct cause-and-effect relationship with specific chemotherapy drugs, and whether some patients may already be predisposed or at higher risk for cognitive decline, she said. Also commenting for Medscape Medical News , Eric Brown, MD, associate scientist and associate chief of geriatric psychiatry at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada, raised concerns about the study's design. One issue, he noted, is that the researchers did not image all patients who received chemotherapy but instead selected those with the most significant cognitive impairment. As a result, the findings may not have reflected outcomes in the average post-chemotherapy patients but rather represent the most severely affected subgroup. Brown also pointed out that the study did not clarify whether this subgroup had comorbid conditions. It's possible, he said, that some individuals may have had Alzheimer's disease or other forms of dementia unrelated to chemotherapy. He agreed that tracking longitudinal changes in both cognitive scores and neuroimaging — comparing patients who receive chemotherapy with those who do not — would be a valuable next step.
